Входя на эту страницу, Вы подтверждаете, что являетесь  медицинским работником.

Status message

Not the entire site translated, but only to "Magazine"

Algorithm of biological therapy for panic disorder

Potanin SS1, Beburishvili AA1, Gantman MV1, Morozova MA1, Mosolov SN2
1Mental Health Research Center
2Moscow Research Institute of Psychiatry, branch of Federal Medical Research Centre of Psychiatry and Narcology of Ministry of Healthcare of the Russian Federation

SUMMARY. The publication presents an algorithm for the biological therapy of Panic Disorder, based on the analysis of Russian and foreign literature sources (clinical studies, meta-analyzes, treatment recommendations, etc.). The psychopharmacotherapy of Panic Disorder is described in detail, including classes of medications, first-choice therapy and recommended actions when it is ineffective, the most frequent mistakes in therapy choice and possible strategies to overcome treatment resistance. These guidelines contain literature references and levels of evidence for every source. In a brief form, the treatment algorithm is presented as a schema. The full list of the literature and recommended sources are listed.

References: 
  • 1. Baldwin D.S., Anderson I.M., Nutt D.J. et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology // Journal of Psychopharmacology. – 2014. – Vol. 28, No. 5. – P. 403–439.
  • 2. American Psychiatric Association. Practice guideline for the treatment of patients with panic disorder. 2nd ed. – Washington, DC: American Psychiatric Association, 2009.
  • 3. World Health Organization et al. The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research. – 1993.
  • 4. Roy-Byrne P., Craske M., Stein M. Panic disorder // The Lancet. – 2006. – Vol. 368, No. 9540. – P. 1023–1032.
  • 5. De Carvalho M.R., Dias G.P., Cosci F. et al. Current findings of fMRI in panic disorder: contributions for the fear neurocircuitry and CBT effects // Expert review of neurotherapeutics. – 2010. – Vol. 10, No. 2. – P. 291–303.
  • 6. Beutel M.E., Stark R., Pan H. et al. Changes of brain activation pre-post short-term psychodynamic inpatient psychotherapy: an fMRI study of panic disorder patients // Psychiatry Research: Neuroimaging. – 2010. – Vol. 184, No. 2. – P. 96–104.
  • 7. Bourin M., Baker G.B., Bradwejn J. Neurobiology of panic disorder // Journal of psychosomatic research. – 1998. – Vol. 44, No. 1. – P. 163–180.
  • 8. Gorman J.M., Kent J.M., Sullivan G.M. et al. Neuroanatomical hypothesis of panic disorder, revised // American Journal of Psychiatry. – 2000. – Vol. 157, No. 4. – P. 493–505.
  • 9. Reiman E.M., Raichle M.E., Butler F.K. et al. A focal brain abnormality in panic disorder, a severe form of anxiety // Nature. – 1984. – No. 10. – P. 683–685.
  • 10. Dresler T., Guhn A., Tupak S.V. et al. Revise the revised? New dimensions of the neuroanatomical hypothesis of panic disorder // Journal of neural transmission. – 2013. – Vol. 120, No. 1. – P. 3–29.
  • 11. Vein A.M., Dyukova G.M., Vorob'eva O.V. i dr. Panicheskie ataki: nevrologicheskie i psikhofiziologicheskie aspekty. – SPb.: Inst. med. marketinga, 1997.
  • 12. Drobizhev M.Yu., Ovchinnikov A.A. Patogeneticheskaya psikhofarmakoterapiya trevozhnykh rasstroistv // Sotsial'naya i klinicheskaya psikhiatriya. – 2010. – Vol. 20, No. 4.
  • 13. Charney D.S., Woods S.W., Goodman W.K. et al. Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks // The American journal of psychiatry. – 1987. – Vol. 144, No. 8. – P. 1030–1036.
  • 14. Neumeister A., Bain E., Nugent A.C. et al. Reduced serotonin type 1A receptor binding in panic disorder // The Journal of neuroscience. – 2004. – Vol. 24, No. 3. – P. 589–591.
  • 15. Johnson P.L., Truitt W., Fitz S.D. et al. A key role for orexin in panic anxiety // Nature medicine. – 2010. – Vol. 16, No. 1. – S. 111–115.
  • 16. Hohoff C. et al. Adenosine A 2A receptor gene: evidence for association of risk variants with panic disorder and anxious personality // Journal of psychiatric research. – 2010. – Vol. 44, No. 14. – P. 930–937.
  • 17. Weissman M.M., Fyer A.J., Haghighi F. et al. Potential panic disorder syndrome: clinical and genetic linkage analysis // American journal of medical genetics. – 2000. – Vol. 96, No. 1. – P. 24–35.
  • 18. Schumacher J., Kristensen A.S., Wendland J.R. et al. The genetics of panic disorder // Journal of medical genetics. – 2011. – Vol. 48, No. 6. – P. 361–368.
  • 19. Vorob'eva O.V. Panicheskie ataki (klinika, diagnostika, printsipy lecheniya). – M.: OOO «AMA-PRESS», 2009. T. 46.
  • 20. Dmitrieva T.B., Krasnov V.N., Neznanov N.G. i dr. Psikhiatriya. Natsional'noe rukovodstvo.– M.: Izdatel'skaya gruppa «GEOTAR-MEDIA», 2009.– 995 s.
  • 21. Ovchinnikov A.A., Rakitskaya N.Yu. Trevozhnye (panicheskie) rasstroistva v obshchemeditsinskoi praktike (diagnostika i terapiya) // Meditsina i obrazovanie v Sibiri. – 2009, № 2.
  • 22. Alonso J., Angermeyer M.C., Bernert S. et al. Disability and quality of life impact of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project // Acta Psychiatrica Scandinavica. – 2004. – Vol. 109, No. s420. – P. 38–46.
  • 23. Batelaan N., Smit F., de Graaf R. et al. Economic costs of full-blown and subthreshold panic disorder // Journal of affective disorders. – 2007. – Vol. 104, No. 1. – P. 127–136.
  • 24. Mendlowicz M.V., Stein M.B. Quality of life in individuals with anxiety disorders // American Journal of Psychiatry. – 2000. – Vol. 157, No. 5. – P. 669–682.
  • 25. Natolochnaya O.V., Cherkasov A.A. Panic attack as the syndrom of the XXI century // European Journal of Psychological Studies. – 2014. – Vol. 1, No. 1. – P. 12–17.
  • 26. DSM-4-TR. – Elsevier Masson, 2004.
  • 27. Bystritskii A.S., Neznanov N.G., Zvartau E.E. Differentsial'naya diagnostika i lechenie panicheskikh rasstroistv // Obozrenie psikhiatrii i meditsinskoi psikhologii im. V.M. Bekhtereva. – 2006, №. 3.
  • 28. Bobrov A.E. Trevozhnye rasstroistva: ikh sistematika, diagnostika i farmakoterapiya // Russkii meditsinskii zhurnal. – 2006. – T. 14, № 4. – S. 328–332.
  • 29. Kolyutskaya E.V. Sovremennye podkhody k psikhofarmakoterapii trevozhnykh rasstroistv // Mezhdunar. nevrol. zhurn. – 2006. – № 4. – S. 141–142.
  • 30. Mosolov S.N., Aleksandrovskii Yu.A., Vovin R.Ya. i dr. Klinicheskaya effektivnost' i perenosimost' Paksila (paroksetina) pri lechenii panicheskogo rasstroistva // Ter. arkhiv. – 2000. – T. 72, № 10. – S. 16–23.
  • 31. Mosolov S.N., Smulevich A.B., Nuller Yu.L. i dr. Mul'titsentrovoe issledovanie effektivnosti i perenosimosti paroksetina (paksil) pri lechenii panicheskogo rasstroistva // Kachestvennaya klinicheskaya praktika. – 2001. – № 2. – S. 3–16.
  • 32. Mosolov S.N. Klinicheskoe primenenie sovremennykh antidepressantov. SPb.: Meditsinskoe informatsionnoe agentstvo, 1995. – 568 s.
  • 33. Mosolov C.N. Trevozhnye i depressivnye rasstroistva: komorbidnost' i terapiya. – M.: Artinfo Pablishing, 2007. – 61 s.
  • 34. Biologicheskie metody terapii psikhicheskikh rasstroistv: dokazatel'naya meditsina – klinicheskoi praktike / pod red. S.N. Mosolova. – M.: Politicheskaya mysl', 2012. – 1080 s.
  • 35. Andrisano C., Chiesa A., Serretti A. Newer antidepressants and panic disorder: A meta-analysis // International clinical psychopharmacology. – 2013. – Vol. 28, No. 1. – P. 33–45.
  • 36. Otto M.W., Tuby K.S., Gould R.A. et al. An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder // American Journal of Psychiatry. – 2001. – Vol. 158, No. 12. – P. 1989–1992.
  • 37. Boshuisen M.L., Slaap B.R., Vester-Blokland E.D. et al. The effect of mirtazapine in panic disorder: an open label pilot study with a singleblind placebo run-in period // International clinical psychopharmacology. – 2001. – Vol. 16, No. 6. – P. 363–368.
  • 38. Ribeiro L., Busnello J.V., Kauer-Sant’Anna M. et al. Mirtazapine versus fluoxetine in the treatment of panic disorder // Brazilian Journal of Medical and Biological Research. – 2001. – Vol. 34, No. 10. – P. 1303–1307.
  • 39. Kruger M.B., Dahl A.A. The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder // European archives of psychiatry and clinical neuroscience. – 1999. – Vol. 249, No. 1. – P. S19–S24.
  • 40. Simon N.M., Kaufman R.E., Hoge E.A. Open-label support for duloxetine for the treatment of panic disorder // CNS neuroscience & therapeutics. – 2009. – Vol. 15, No. 1. – P. 19–23.
  • 41. Blaya C., Seganfredo A.C., Dornelles M. et al. The efficacy of milnacipran in panic disorder: an open trial // International clinical psychopharmacology. – 2007. – Vol. 22, No. 3. – P. 153–158.
  • 42. Marks I.M., Swinson R.P., Basoglu M. et al. Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto // The British Journal of Psychiatry. – 1993. – Vol. 162, No. 6. – P. 776–787.
  • 43. Tesar G.E., Rosenbaum J.F., Pollack M.H. et al. Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder // Journal of Clinical Psychiatry. – 1991. – No. 52. – P. 69–76.
  • 44. Van Balkom A.J., Nauta M., Bakker A. Meta-analysis on the treatment of panic disorder with agoraphobia: review and re-examination // Clinical Psychology & Psychotherapy. – 1995. – Vol. 2, No. 1. – P. 1–14.
  • 45. Van Balkom A.J., Bakker A., Spinhoven P. et al. A meta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments // The Journal of nervous and mental disease. – 1997. – Vol. 185, No. 8. – P. 510–516.
  • 46. Ontiveros A., Fontaine R. Sodium valproate and clonazepam for treatment-resistant panic disorder // Journal of Psychiatry and Neuroscience. – 1992. – Vol. 17, No. 2. – P. 78.
  • 47. Woodman C.L., Noyes R. Panic disorder: treatment with valproate // Journal of Clinical Psychiatry. – 1994. – No. 55. – P. 134–136.
  • 48. Pande A.C., Pollack M.H., Crockatt J. et al. Placebo-controlled study of gabapentin treatment of panic disorder // Journal of clinical psychopharmacology. – 2000. – Vol. 20, No. 4. – P. 467–471.
  • 49. Pollack M.H., Matthews J., Scott E.L. Gabapentin as a potential treatment for anxiety disorders // American Journal of Psychiatry. – 1998. – Vol. 155, No. 7. – P. 992–993.
  • 50. Zwanzger P., Baghai T.C., Schule C. et al. Tiagabine improves panic and agoraphobia in panic disorder patients // The Journal of clinical psychiatry. – 2001. – Vol. 62, No. 8. – P. 656–657.
  • 51. Simon N.M., Hoge E.A., Fischmann D. et al. An open-label trial of risperidone augmentation for refractory anxiety disorders // The Journal of clinical psychiatry. – 2006. – Vol. 67, No. 3. – P. 381–385.
  • 52. Sepede G., De Berardis D., Gambi F. et al. Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial // Journal of clinical psychopharmacology. – 2006. – Vol. 26, No. 1. – P. 45–49.
  • 53. Hoge E. A. et al. Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder // CNS spectrums. – 2008. – Vol. 13, No. 06. – P. 522–525.
  • 54. Goddard A.W., Mahmud W., Medlock C. et al. A controlled trial of quetiapine XR coadministration treatment of SSRI-resistant panic disorder. // Annals of general psychiatry. – 2015. – Vol. 14, No. 1. – P. 1.
  • 55. Sheehan D.V., Raj A.B., Sheehan K.H. et al. The relative efficacy of buspirone, imipramine and placebo in panic disorder: A preliminary report // Pharmacology Biochemistry and Behavior. – 1988. – Vol. 29, No. 4. – P. 815–817.
  • 56. Sheehan D.V., Davidson J., Manschreck T. et al. Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias // Journal of clinical psychopharmacology. – 1983. – Vol. 3, No. 1. – P. 28–31.
  • 57. Munjack D.J., Crocker B., Cabe D. et al. Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks // Journal of clinical psychopharmacology. – 1989. – Vol. 9, No. 1. – P. 22–27.
  • 58. Bakker A., van Balkom AJ, Spinhoven P. SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis // Acta Psychiatrica Scandinavica. – 2002. – Vol. 106, No. 3. – P. 163–167.
  • 59. Pollack M.H., Lepola U., Koponen H. et al. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder // Depression and anxiety. – 2007. – Vol. 24, No. 1. – P. 1–14.
  • 60. Batelaan N.M., Van Balkom A.J., Stein D.J. Evidence-based pharmacotherapy of panic disorder: An update // International Journal of Neuropsychopharmacology. – 2012. – Vol. 15, No. 3. – P. 403–415.
  • 61. Boyer W. Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis // International Clinical Psychopharmacology. – 1995. – Vol. 10, No. 1. – P. 45–50.
  • 62. Gartlehner G., Hansen R.A., Morgan L.C. et al. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder an updated meta-analysis // Annals of Internal Medicine. – 2011. – Vol. 155, No. 11. – P. 772–785
  • 63. Serretti A., Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants a meta-analysis // Journal of Clinical Psychopharmacology. – 2009. – Vol. 29, No. 3. – P. 259–266.
  • 64. Sinclair L.I., Christmas D.M., Hood S.D. et al. Antidepressant induced jitteriness/anxiety syndrome: Systematic review // The British Journal of Psychiatry. – 2009. – Vol. 194, No. 6. – P. 483–490.
  • 65. Monteiro W.O., Noshirvani H.F., Marks I.M. et al. Anorgasmia from clomipramine in obsessive-compulsive disorder: a controlled trial // The British Journal of Psychiatry. – 1987. – Vol. 151, No. 1. – P. 107–112.
  • 66. Noyes R.J., Garvey M.J., Cook B.L. et al. Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: results of a naturalistic follow-up study // Journal of Clinical Psychiatry. – 1989. – No. 50. – P. 163–169.
  • 67. Soyinka A., Lawley D. Antidepressant treatment for depression in the elderly // Geriatric Medicine-London. – 2006. – Vol. 36, No. 2. – P. 61.
  • 68. Goddard A.W., Brouette T., Almai A. Early coadministration of clonazepam with sertraline for panic disorder // Archives of General Psychiatry. – 2001. – Vol. 58, No. 7. – P. 681–686.
  • 69. Pollack M.H., Simon N.M., Worthington J.J. et al. Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder // Journal of Psychopharmacology. – 2003. – Vol. 17, No. 3. – P. 276–282.
  • 70. Woods S.W., Nagy L.M., Koleszar A.S. et al. Controlled trial of alprazolam supplementation during imipramine treatment of panic disorder // Journal of Clinical Psychopharmacology. – 1992. – Vol. 12, No. 1. – P. 32–38.
  • 71. Seredenin S.B., Voronina T.A., Neznamov G.G. i dr. Fenazepam: 25 let v meditsinskoi praktike. – M: Nauka, 2007. – 381 s.
  • 72. Burrows G.D., Norman T.R. The treatment of panic disorder with benzodiazepines // Panic Disorder: Clinical Diagnosis, Management and Mechanisms. – 1999. – P. 145–158.
  • 73. Offidani E., Guidi J., Tomba E. et al. Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders: a systematic review and meta-analysis // Psychotherapy and Psychosomatics. – 2013. – Vol. 82, No. 6. – P. 355–362.
  • 74. Pollack M.H., Otto M.W., Tesar G.E. et al. Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder // Journal of Clinical Psychopharmacology. – 1993. – Vol. 13, No. 4. – P. 257–263.
  • 75. Karch S.B. et al. (ed.). Drug Abuse Handbook. – CRC press, 2006. – 1138 p.
  • 76. Pogosov A.V., Pogosova I.A., Kovalenko A. Yu. O komorbidnosti alkogol'noi zavisimosti i panicheskikh rasstroistv // Voprosy narkologii. – 2004. – № 1. – S. 10–19.
  • 77. Cox B.J., Norton G.R., Swinson R.P. et al. Substance abuse and panic-related anxiety: a critical review // Behaviour Research and Therapy. – 1990. – Vol. 28, No. 5. – P. 385–393.
  • 78. Dannon P.N., Lowengrub K., Amiaz R. et al. Comorbid cannabis use and panic disorder: short term and long term follow-up study // Human Psychopharmacology: Clinical and Experimental. – 2004. – Vol. 19, No. 2. – P. 97–101.
  • 79. Kushner M.G., Abrams K., Thuras P. et al. Follow-up study of anxiety disorder and alcohol dependence in comorbid alcoholism treatment patients // Alcoholism: Clinical and Experimental Research. – 2005. – Vol. 29, No. 8. – P. 1432–1443.
  • 80. Benítez C.I P., Smith K., Vasile R.G. et al. Use of benzodiazepines and selective serotonin reuptake inhibitors in middle-aged and older adults with anxiety disorders: a longitudinal and prospective study // The American Journal of Geriatric Psychiatry. – 2008. – Vol. 16, No. 1. – P. 5–13.
  • 81. Westra H.A., Stewart S.H., Conrad B.E. Naturalistic manner of benzodiazepine use and cognitive behavioral therapy outcome in panic disorder with agoraphobia // Journal of Anxiety Disorders. – 2002. – Vol. 16, No. 3. – P. 233–246.
  • 82. Shear M.K., Brown T.A., Barlow D.H., Money R., Sholomskas D.E., Woods S.W., Gorman J.M., Papp L.A. Multicenter collaborative Panic Disorder Severity Scale // American Journal of Psychiatry. – 1997. – Vol. 154. – P. 1571–1575.
  • 83. Hamilton M. The assessment of anxiety states by rating // Br J Med Psychol. – 1959. – Vol. 32. – P. 50–55.
  • 84. Mukherjee S., Sullivan G., Perry D. et al. Adherence to treatment among economically disadvantaged patients with panic disorder // Psychiatric Services. – 2006. – Vol. 57, No. 12. – P. 1745–1750.
  • 85. Ballenger J.C., Wheadon D.E., Steiner M. Double-blind, fixeddose, placebo-controlled study of paroxetine in the treatment of panic disorder // American Journal of Psychiatry. – 1998. – Vol. 155, No. 1. – P. 36–42.
  • 86. Michelson D., Allgulander C., Dantendorfer K. et al. Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder – randomised, placebo-controlled trial // The British Journal of Psychiatry. – 2001. – Vol. 179, No. 6. – P. 514–518.
  • 87. Michelson D., Lydiard R.B., Pollack M.H. et al. Outcome assessment and clinical improvement in panic disorder: Evidence from a randomized controlled trial of fluoxetine and placebo // American Journal of Psychiatry. – 1998. – Vol. 155, No. 11. – P. 1570–1577.
  • 88. Johnson J., Weissman M.M., Klerman G.L. Panic disorder, comorbidity, and suicide attempts // Archives of General Psychiatry. – 1990. – Vol. 47, No. 9. – P. 805–808.
  • 89. Lesser I.M., Rubin R.T., Rifkin A. et al. Secondary depression in panic disorder and agoraphobia: II. dimensions of depressive symptomatology and their response to treatment // Journal of Affective Disorders. – 1989. – Vol. 16, No. 1. – P. 49–58.
  • 90. Roy-Byrne P., Stang P., Wittchen H. et al. Lifetime panic-depression comorbidity in the National Comorbidity Survey. Association with symptoms, impairment, course and help-seeking // The British Journal of Psychiatry. – 2000. – Vol. 176, No. 3. – P. 229–235.
  • 91. Kreditor D., Smulevich A. B. Panicheskoe rasstroistvo i komorbidnye sostoyaniya // Trevoga i obsessii. – M., 1998. – S. 66–75.
  • 92. Medvedev V.E. Psikhicheskie rasstroistva pri serdechno-sosudistykh zabolevaniyakh // Meditsina neotlozhnykh sostoyanii. – 2011. – T. 1, № 2. – S. 32–33.
  • 93. Fleet R.P., Dupuis G., Marchand A. et al. Panic disorder in emergency department chest pain patients: prevalence, comorbidity, suicidal ideation, and physician recognition // The American Journal of Medicine. – 1996. – Vol. 101, No. 4. – P. 371–380.
  • 94. Gomez-Caminero A., Blumentals W.A., Russo L.J. et al. Does panic disorder increase the risk of coronary heart disease? A cohort study of a national managed care database // Psychosomatic Medicine. – 2005. – Vol. 67, No. 5. – P. 688–691.
  • 95. Hasler G., Gergen P.J., Kleinbaum D.G. et al. Asthma and panic in young adults: a 20-year prospective community study // American Journal of Respiratory and Critical Care Medicine. – 2005. – Vol. 171, No. 11. – P. 1224–1230.
  • 96. Chen Y.H., Hu C.J., Lee H.C. et al. An increased risk of stroke among panic disorder patients: a 3-year follow-up study // The Canadian Journal of Psychiatry. – 2010. – Vol. 55, No. 1. – P. 43–49.
  • 97. Tellez-Zenteno J.F., Patten S.B., Jette N. et al. Psychiatric comorbidity in epilepsy: a population-based analysis // Epilepsia. – 2007. – Vol. 48, No. 12. – P. 2336–2344.
  • 98. Tiller J.W., Bouwer C., Behnke K. Moclobemide and fluoxetine for panic disorder // European Archives of Psychiatry and Clinical Neuroscience. – 1999. – Vol. 249, No. 1. – P. 7–10.
  • 99. Carli V., Sarchiapone M., Camardese G. et al. Mirtazapine in the treatment of panic disorder (letter) // Archives of general psychiatry. – 2002. – Vol. 59, No. 7. – P. 661–662.
  • 100. Carpenter L.L., Leon Z., Yasmin S. et al. Clinical experience with mirtazapine in the treatment of panic disorder // Annals of Clinical Psychiatry. – 1999. – Vol. 11, No. 2. – P. 81–86.
  • 101. Montanes-Rada F., Lucas-Taracena M.T., Sanchez-Romero S. Mirtazapine versus paroxetine in panic disorder: an open study // International Journal of Psychiatry in Clinical Practice. – 2005. – Vol. 9, No. 2. – P. 87–93.
  • 102. Sarchiapone M., Amore M., De Risio S. et al. Mirtazapine in the treatment of panic disorder: an open-label trial // International Clinical Psychopharmacology. – 2003. – Vol. 18, No. 1. – P. 35–38.
  • 103. Baetz M., Bowen R.C. Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy // The Canadian Journal of Psychiatry. – 1998. – Vol. 43, No. 1. – P. 73–77.
  • 104. Primeau F., Fontaine R., Beauclair L. Valproic acid and panic disorder // The Canadian Journal of Psychiatry / La Revue canadienne de psychiatrie. – 1990. – No. 3. – P. 248–250.
  • 105. Hirschmann S., Dannon P.N., Iancu I. et al. Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trial // Journal of Clinical Psychopharmacology. – 2000. – Vol. 20, No. 5. – P. 556–559.
  • 106. Tiffon L., Coplan J.D., Papp L.A. et al. Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients // Journal of Clinical Psychiatry. – 1994. – No. 55. – P. 66–69.
  • 107. Li H., Wang, J., Li, C. et al. Repetitive transcranial magnetic stimulation (rTMS) for panic disorder in adults // The Cochrane Library. – 2014.
  • 108. Pigot M., Loo C., Sachdev P. Repetitive transcranial magnetic stimulation as treatment for anxiety disorders // Expert Review of Neurotherapeutics. – 2008. – Vol. 8, No. 10. – P. 1449–1455.
  • 109. Zwanzger P., Minov C., Ella R. et al. Transcranial magnetic stimulation for panic // American Journal of Psychiatry. – 2002. – No. 159. – P. 315–316.
  • 110. Zwanzger P., Fallgatter A.J., Zavorotnyy M. Anxiolytic effects of transcranial magnetic stimulation–an alternative treatment option in anxiety disorders? // Journal of Neural Transmission. – 2009. – Vol.116, No. 6. – P. 767–775.
  • 111. Donovan M.R., Glue P., Kolluri S. et al. Comparative efficacy of antidepressants in preventing relapse in anxiety disorders – a metaanalysis // Journal of Affective Disorders. – 2010. – Vol. 123, No. 1. – P. 9–16.
  • 112. Marchesi C. Pharmacological management of panic disorder // Neuropsychiatric Disease and Treatment. – 2008. – Vol. 4, No. 1. – P. 93.
  • 113. McHugh R.K., Smits J.A.J., Otto M.W. Empirically supported treatments for panic disorder // Psychiatric Clinics of North America. – 2009. – Vol. 32, No. 3. – S. 593–610.
  • 114. Rickels K., Schweizer E., Weiss S. et al. Maintenance drug treatment for panic disorder: II. short- and long-term outcome after drug taper // Archives of General Psychiatry. – 1993. – Vol. 50, No. 1. – P. 61–68.
  • 115. Tiganov A. S. Psikhiatriya: Rukovodstvo dlya vrachei. V 2 t. – M.: Meditsina, 2012. – S. 510–533.
  • 116. Nardi A.E., Freire R.C., Mochcovitch M.D. et al. A randomized, naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetine // Journal of Clinical Psychopharmacology. – 2012. – Vol. 32, No. 1. – P. 120–126.
  • 117. Soumerai S.B., Simoni-Wastila L., Singer C. et al. Lack of relationship between long-term use of benzodiazepines and escalation to high dosages // Psychiatric Services. – 2003. – No. 54. – P. 1006–1011.
  • 118. Wolf B., Griffiths R. R. Physical dependence on benzodiazepines: differences within the class // Drug and Alcohol Dependence. – 1991. – Vol. 29, No. 2. – P. 153–156.
  • 119. Furukawa T.A., Watanabe N., Churchill R. Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia // The Cochrane Library. – 2007.
  • 120. Schmidt N.B., Keogh M.E. Treatment of panic // Annual Review of Clinical Psychology. – 2010. – Vol. 6. – P. 241–256.